Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A building project to extend the Kennedy Institute of Rheumatology building with a new floor will create much needed space for the Institute to expand, particularly in the areas of data science and clinical trials.

Kennedy Institute building
The new floor will enable the Institute to expand its data science and clinical trials programmes

Housing more than 25 research groups, the Kennedy Institute of Rheumatology is at the forefront of research in the areas of immunity and microbiome, inflammation biology, and tissue remodelling and regeneration. Approximately 200 researchers, support staff and students work towards making fundamental discoveries about biological processes that help in the understanding of inflammatory and degenerative diseases such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and cancer.

A strategic objective of the Institute is to accelerate understanding of these diseases through the application of data science-based approaches complementing its long-established lab-based research. The Institute has invested substantially in this area, building a core of expertise and technologies encompassing single cell genomics, statistical genetics, microbial genomics, computational biology and clinical trials.

The full story is available on the Nuffield Department of Orthopaedics,Rheumatology & Musculoskeletal Sciences website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.